DurVena, Inc.
Developer of a photochemical tissue passivation therapy for reinforcing harvested vein grafts prior to arterial implantation. The technology uses a topically applied photosensitizer activated by light to increase collagen crosslinking in the vein adventitia, with published preclinical data reporting increased vein stiffness and reduced intimal hyperplasia. The program has been advanced through preclinical GLP testing, is covered by an international patent portfolio, and has received FDA Breakthrough Device designation.
Industries
Nr. of Employees
small (1-50)
Products
Photochemical tissue passivation system for vein graft preparation
A surgical system that applies a photosensitizer to harvested veins and uses light activation to create adventitial collagen crosslinks prior to arterial implantation, intended to increase graft stiffness and reduce intimal hyperplasia.
Photochemical tissue passivation system for vein graft preparation
A surgical system that applies a photosensitizer to harvested veins and uses light activation to create adventitial collagen crosslinks prior to arterial implantation, intended to increase graft stiffness and reduce intimal hyperplasia.
Services
Training and support for surgical teams to implement the tissue passivation protocol and to participate in upcoming clinical trials.
Training and support for surgical teams to implement the tissue passivation protocol and to participate in upcoming clinical trials.
Expertise Areas
- Vascular graft reinforcement
- Preclinical GLP study design and execution (small and large animal models)
- Photosensitizer-activated tissue modification
- Medical device regulatory strategy (Breakthrough Device pathway)
Key Technologies
- Photochemical tissue passivation
- Photosensitizer-mediated collagen crosslinking
- LED-based light activation
- GLP animal models
News & Updates
Peer-reviewed preclinical work reporting that photochemical tissue passivation reduces vein graft wall thickness, luminal diameter, and intimal hyperplasia in animal models.
The vein graft preparation system has received Breakthrough Device designation from the U.S. Food and Drug Administration.
Extensive preclinical testing reported increases in vein stiffness (reported up to 5x) and reductions in intimal hyperplasia (reported up to ~70%) following photochemical tissue passivation.
Peer-reviewed preclinical work reporting that photochemical tissue passivation reduces vein graft wall thickness, luminal diameter, and intimal hyperplasia in animal models.
The vein graft preparation system has received Breakthrough Device designation from the U.S. Food and Drug Administration.
Extensive preclinical testing reported increases in vein stiffness (reported up to 5x) and reductions in intimal hyperplasia (reported up to ~70%) following photochemical tissue passivation.